Incyte

Pharmaceuticals
INCY
$ 78 4.6
Share price
$ 17 bn
Market Cap
$ 14 bn
Enterprise Value

Carbon footprint

0.57 Ton
GHG emissions per $ 1 mln investment
0.02x the weighted average for S&P 500
FY2020
How is this calculated?
-15%
YOY change in GHG emissions
Stronger than the -8.7% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-20%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Incyte aims to achieve carbon neutrality for Scope 1 + 2 by 2025


This target has not been verified as science based according to SBTi
Incyte's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Incyte's GHG emissions (location-based) (Kt of CO2e)
Incyte's Carbon intensity (Tons per 1 USDm)

Incyte's carbon footprint

Incyte reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 7.8 Kt (-1.3 /-14.5% y-o-y). Also positively, carbon intensity decreased to 2.9 t (-1.4 /-32.6% y-o-y).

Incyte's Scope 3 emissions was down at 0.82 Kt (-2.4 /-74.8% y-o-y).

The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2025, which translates into the estimated reduction of -1.6 Kt per annum over the period of FY2021 - FY2025. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Incyte aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2025. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...